Eyepoint Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Eyepoint Pharmaceuticals
EYPT Stock  USD 8.05  0.32  4.14%   
Eyepoint Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Eyepoint Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Eyepoint Pharmaceuticals financial statements helps investors assess Eyepoint Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Eyepoint Pharmaceuticals' valuation are summarized below:
Gross Profit
-64.5 M
Profit Margin
(2.27)
Market Capitalization
549.4 M
Enterprise Value Revenue
6.4688
Revenue
45.7 M
There are currently one hundred twenty fundamental signals for Eyepoint Pharmaceuticals that can be evaluated and compared over time across rivals. All traders should verify Eyepoint Pharmaceuticals' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 66 M in 2025. Enterprise Value is likely to drop to about 66.5 M in 2025

Eyepoint Pharmaceuticals Total Revenue

55.57 Million

Check Eyepoint Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eyepoint Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 396.7 K, Interest Expense of 1.6 M or Total Revenue of 55.6 M, as well as many indicators such as Price To Sales Ratio of 20.8, Dividend Yield of 0.0 or PTB Ratio of 3.59. Eyepoint financial statements analysis is a perfect complement when working with Eyepoint Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Eyepoint Pharmaceuticals Correlation against competitors.
For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.

Eyepoint Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets428.9 M408.5 M129.2 M
Slightly volatile
Short and Long Term Debt Total5.4 M5.6 M21 M
Pretty Stable
Other Current Liabilities21.9 M20.9 M8.1 M
Slightly volatile
Total Current Liabilities76.4 M72.8 M21.7 M
Slightly volatile
Total Stockholder Equity321.6 M306.3 M84.3 M
Slightly volatile
Property Plant And Equipment Net12.4 M11.8 M3.2 M
Slightly volatile
Cash339.6 M323.5 M88.6 M
Slightly volatile
Non Current Assets Total8.9 M9.3 M12.2 M
Pretty Stable
Non Currrent Assets Other281.2 K172.5 K297.9 K
Slightly volatile
Cash And Short Term Investments399.7 M380.7 M107.3 M
Slightly volatile
Net Receivables879.5 K925.8 K3.9 M
Slightly volatile
Common Stock Total Equity29.1 K30.6 K421.1 K
Slightly volatile
Liabilities And Stockholders Equity428.9 M408.5 M129.2 M
Slightly volatile
Other Current Assets10.9 M10.4 M4.9 M
Slightly volatile
Other Stockholder Equity1.2 B1.2 B518.5 M
Slightly volatile
Total Liabilities107.3 M102.2 M44.9 M
Slightly volatile
Property Plant And Equipment Gross15.5 M14.7 M3.8 M
Slightly volatile
Total Current Assets416.3 M396.5 M116.6 M
Slightly volatile
Intangible Assets19.1 M20.5 M14.4 M
Slightly volatile
Common Stock53.5 K56.4 K289.3 M
Pretty Stable
Common Stock Shares Outstanding47 M44.7 M15.2 M
Slightly volatile
Accounts Payable7.9 M7.5 M4 M
Slightly volatile
Other Assets192.9 K172.5 K202.8 K
Pretty Stable
Accumulated Other Comprehensive Income1.2 M777.6 K873.7 K
Pretty Stable
Property Plant Equipment1.3 M1.2 M689.5 K
Slightly volatile
Current Deferred Revenue33 M34.7 M174 M
Slightly volatile
Short Term Debt481.4 K506.7 K174.8 M
Slightly volatile
Other Liabilities8.6 M16.3 M9.2 M
Slightly volatile
Capital Surpluse467 M881.9 M467.2 M
Slightly volatile
Deferred Long Term Liabilities9.8 M15.6 M10.2 M
Slightly volatile
Net Invested Capital321.6 M306.3 M96.3 M
Slightly volatile
Net Working Capital340 M323.8 M94.5 M
Slightly volatile
Long Term Debt Total34.1 M33.7 M25.3 M
Slightly volatile
Short and Long Term Debt11.1 M9.4 M13.9 M
Slightly volatile
Capital Lease Obligations4.4 M5.6 M3.8 M
Slightly volatile
Capital Stock39 K44.1 K81.8 K
Slightly volatile

Eyepoint Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization396.7 K417.6 K1.6 M
Pretty Stable
Total Revenue55.6 M52.9 M21.3 M
Slightly volatile
Other Operating Expenses146.2 M139.2 M57.5 M
Slightly volatile
Research Development78.1 M74.4 M26.1 M
Slightly volatile
Total Operating Expenses138.9 M132.3 M54.7 M
Slightly volatile
Selling General Administrative48.4 M46.1 M19.2 M
Slightly volatile
Cost Of Revenue4 M4.2 M9.1 M
Slightly volatile
Selling And Marketing Expenses17 M13.4 M10.2 M
Slightly volatile
Interest Income8.4 M8 M3 M
Slightly volatile
Reconciled Depreciation506.9 K533.6 K1.3 M
Pretty Stable

Eyepoint Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow115.5 M110 M45.2 M
Slightly volatile
Depreciation396.7 K417.6 K1.5 M
Very volatile
Capital Expenditures4.2 M4 M999.6 K
Slightly volatile
End Period Cash Flow339.6 M323.5 M88.6 M
Slightly volatile
Change To Netincome46.3 M44.1 M19.4 M
Slightly volatile
Issuance Of Capital Stock137.3 M260.1 M76.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio20.821.8937.5718
Slightly volatile
PTB Ratio3.593.787.929
Slightly volatile
Days Sales Outstanding6.987.3495.2014
Slightly volatile
Book Value Per Share7.487.875.4445
Slightly volatile
Average Payables2.8 M3.2 M3.5 M
Slightly volatile
Stock Based Compensation To Revenue0.350.240.4388
Pretty Stable
Capex To Depreciation7.096.761.4914
Slightly volatile
PB Ratio3.593.787.929
Slightly volatile
EV To Sales14.2414.9999.5502
Slightly volatile
Payables Turnover0.780.825.1081
Slightly volatile
Sales General And Administrative To Revenue0.951.01.9787
Slightly volatile
Research And Ddevelopement To Revenue1.541.622.3012
Slightly volatile
Capex To Revenue0.08270.0870.0726
Slightly volatile
Cash Per Share8.269.796.1781
Pretty Stable
Days Payables Outstanding556589490
Very volatile
Intangibles To Total Assets0.09440.09930.1953
Slightly volatile
Current Ratio5.866.275.8579
Pretty Stable
Receivables Turnover54.0251.4517.6185
Slightly volatile
Graham Number18.2919.2522.1428
Slightly volatile
Shareholders Equity Per Share7.487.875.4107
Pretty Stable
Debt To Equity0.02010.02121.5229
Very volatile
Capex Per Share0.09780.10.0644
Pretty Stable
Average Receivables391.8 K440.8 K480.6 K
Slightly volatile
Revenue Per Share1.291.361.8932
Pretty Stable
Interest Debt Per Share0.170.182.3225
Very volatile
Debt To Assets0.01510.01590.5061
Slightly volatile
Price Book Value Ratio3.593.787.929
Slightly volatile
Days Of Payables Outstanding556589490
Very volatile
Ebt Per Ebit1.411.081.1649
Pretty Stable
Company Equity Multiplier1.71.22.9181
Pretty Stable
Long Term Debt To Capitalization0.480.270.4857
Pretty Stable
Total Debt To Capitalization0.01980.02080.4358
Slightly volatile
Debt Equity Ratio0.02010.02121.5229
Very volatile
Quick Ratio5.896.25.8437
Pretty Stable
Net Income Per E B T0.750.91.0016
Pretty Stable
Cash Ratio4.485.114.1779
Pretty Stable
Days Of Sales Outstanding6.987.3495.2014
Slightly volatile
Price To Book Ratio3.593.787.929
Slightly volatile
Fixed Asset Turnover4.915.1713.5083
Pretty Stable
Debt Ratio0.01510.01590.5061
Slightly volatile
Price Sales Ratio20.821.8937.5718
Slightly volatile
Asset Turnover0.150.120.2181
Very volatile
Price Fair Value3.593.787.929
Slightly volatile

Eyepoint Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap66 M69.5 M80.5 M
Slightly volatile
Enterprise Value66.5 M70 M72 M
Slightly volatile

Eyepoint Fundamental Market Drivers

Cash And Short Term Investments331.1 M

Eyepoint Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Eyepoint Pharmaceuticals Financial Statements

Eyepoint Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Eyepoint Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Eyepoint Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Eyepoint Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue34.7 M33 M
Total Revenue52.9 M55.6 M
Cost Of Revenue4.2 M4 M
Stock Based Compensation To Revenue 0.24  0.35 
Sales General And Administrative To Revenue 1.00  0.95 
Research And Ddevelopement To Revenue 1.62  1.54 
Capex To Revenue 0.09  0.08 
Revenue Per Share 1.36  1.29 
Ebit Per Revenue(1.47)(1.54)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Eyepoint Stock Analysis

When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY